Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy

Clicks: 142
ID: 276301
2023
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #36 of 44 articles by views in BMC cancer

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background There is no standard treatment recommended at category 1 level in international guidelines for subsequent therapy after cyclin-dependent kinase 4/6 inhibitor (CDK4/6) based therapy. We aimed to evaluate which subsequent treatment oncologists prefer in patients with disease progression under CDKi. In addition, we aimed to show the effectiveness of systemic treatments after CDKi and whether there is a survival difference between hormonal treatments (monotherapy vs. mTOR-based). Methods A total of 609 patients from 53 centers were included in the study. Progression-free-survivals (PFS) of subsequent treatments (chemotherapy (CT, n:434) or endocrine therapy (ET, n:175)) after CDKi were calculated. Patients were evaluated in three groups as those who received CDKi in first-line (group A, n:202), second-line (group B, n: 153) and ≥ 3rd-line (group C, n: 254). PFS was compared according to the use of ET and CT. In addition, ET was compared as monotherapy versus everolimus-based combination therapy. Results The median duration of CDKi in the ET arms of Group A, B, and C was 17.0, 11.0, and 8.5 months in respectively; it was 9.0, 7.0, and 5.0 months in the CT arm. Median PFS after CDKi was 9.5 (5.0–14.0) months in the ET arm of group A, and 5.3 (3.9–6.8) months in the CT arm (p = 0.073). It was 6.7 (5.8–7.7) months in the ET arm of group B, and 5.7 (4.6–6.7) months in the CT arm (p = 0.311). It was 5.3 (2.5–8.0) months in the ET arm of group C and 4.0 (3.5–4.6) months in the CT arm (p = 0.434). Patients who received ET after CDKi were compared as those who received everolimus-based combination therapy versus those who received monotherapy ET: the median PFS in group A, B, and C was 11.0 vs. 5.9 (p = 0.047), 6.7 vs. 5.0 (p = 0.164), 6.7 vs. 3.9 (p = 0.763) months. Conclusion Physicians preferred CT rather than ET in patients with early progression under CDKi. It has been shown that subsequent ET after CDKi can be as effective as CT. It was also observed that better PFS could be achieved with the subsequent everolimus-based treatments after first-line CDKi compared to monotherapy ET.
Reference Key
karacin2023efficacybmc Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Karacin, Cengiz;Oksuzoglu, Berna;Demirci, Ayşe;Keskinkılıç, Merve;Baytemür, Naziyet Köse;Yılmaz, Funda;Selvi, Oğuzhan;Erdem, Dilek;Avşar, Esin;Paksoy, Nail;Demir, Necla;Göksu, Sema Sezgin;Türker, Sema;Bayram, Ertuğrul;Çelebi, Abdüssamet;Yılmaz, Hatice;Kuzu, Ömer Faruk;Kahraman, Seda;Gökmen, İvo;Sakin, Abdullah;Alkan, Ali;Nayır, Erdinç;Uğraklı, Muzaffer;Acar, Ömer;Ertürk, İsmail;Demir, Hacer;Aslan, Ferit;Sönmez, Özlem;Korkmaz, Taner;Celayir, Özde Melisa;Karadağ, İbrahim;Kayıkçıoğlu, Erkan;Şakalar, Teoman;Öktem, İlker Nihat;Eren, Tülay;Urul, Enes;Mocan, Eda Eylemer;Kalkan, Ziya;Yıldırım, Nilgün;Ergün, Yakup;Akagündüz, Baran;Karakaya, Serdar;Kut, Engin;Teker, Fatih;Demirel, Burçin Çakan;Karaboyun, Kubilay;Almuradova, Elvina;Ünal, Olçun Ümit;Oyman, Abdilkerim;Işık, Deniz;Okutur, Kerem;Öztosun, Buğra;Gülbağcı, Burcu Belen;Kalender, Mehmet Emin;Şahin, Elif;Seyyar, Mustafa;Özdemir, Özlem;Selçukbiricik, Fatih;Kanıtez, Metin;Dede, İsa;Gümüş, Mahmut;Gökmen, Erhan;Yaren, Arzu;Menekşe, Serkan;Ebinç, Senar;Aksoy, Sercan;İmamoğlu, Gökşen İnanç;Altınbaş, Mustafa;Çetin, Bülent;Uluç, Başak Oyan;Er, Özlem;Karadurmuş, Nuri;Erdoğan, Atike Pınar;Artaç, Mehmet;Tanrıverdi, Özgür;Çiçin, İrfan;Şendur, Mehmet Ali Nahit;Oktay, Esin;Bayoğlu, İbrahim Vedat;Paydaş, Semra;Aydıner, Adnan;Salim, Derya Kıvrak;Geredeli, Çağlayan;Yavuzşen, Tuğba;Doğan, Mutlu;Hacıbekiroğlu, İlhan;
Journal BMC cancer
Year 2023
DOI
136
URL
https://doi.org/10.1186/s12885-023-10609-8
Keywords
neoplasms. tumors. oncology. including cancer and carcinogens

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.